東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Intravitreal delivery of corticoster...

University of Florida.

FindBook

Google Book

Amazon

博客來

Intravitreal delivery of corticosteroid nanoparticles.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Intravitreal delivery of corticosteroid nanoparticles./
作者:	Mudunuri, Keerti.
面頁冊數:	109 p.
附註:	Adviser: Guenther Hochhaus.
Contained By:	Dissertation Abstracts International70-02B.
標題:	Health Sciences, Ophthalmology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3347160
ISBN:	9781109026467

Intravitreal delivery of corticosteroid nanoparticles.
Mudunuri, Keerti.

Intravitreal delivery of corticosteroid nanoparticles. - 109 p.

Adviser: Guenther Hochhaus.

Thesis (Ph.D.)--University of Florida, 2008.

Age-related macular degeneration and diabetic retinopathy occurring in the posterior region of the eye are the leading causes of blindness among the elderly. Treatments for these diseases currently include laser photocoagulation and photodynamic therapy. However, aforementioned methods help in eliminating only the existing neovascularization but do not treat the cause of the disease resulting in reoccurrence. Recently corticosteroids are being used to treat posterior ocular diseases due to their angiostatic and antipermeable properties. The rationale for the use of corticosteroids for these conditions is their ability to inhibit growth factors like vascular endothelial growth factor (VEGF). Drug delivery to the posterior segment of the eye is very challenging. One of the major concerns with intravitreal delivery is that repeated injections are disagreeable and lead to further complications. Sustained release systems including microspheres, liposomes and other implant devices offer an excellent alternative to multiple intravitreous injections.

ISBN: 9781109026467Subjects--Topical Terms:

1019445
Health Sciences, Ophthalmology.

Intravitreal delivery of corticosteroid nanoparticles.
LDR:03524nam 2200313 a 45 001 855264
005 20100708
008 100708s2008 ||||||||||||||||| ||eng d
020 $a 9781109026467
035 $a (UMI)AAI3347160
035 $a AAI3347160
040 $a UMI $c UMI
100 1 $a Mudunuri, Keerti. $3 1021831
245 1 0 $a Intravitreal delivery of corticosteroid nanoparticles.
300 $a 109 p.
500 $a Adviser: Guenther Hochhaus.
500 $a Source: Dissertation Abstracts International, Volume: 70-02, Section: B, page: 0962.
502 $a Thesis (Ph.D.)--University of Florida, 2008.
520 $a Age-related macular degeneration and diabetic retinopathy occurring in the posterior region of the eye are the leading causes of blindness among the elderly. Treatments for these diseases currently include laser photocoagulation and photodynamic therapy. However, aforementioned methods help in eliminating only the existing neovascularization but do not treat the cause of the disease resulting in reoccurrence. Recently corticosteroids are being used to treat posterior ocular diseases due to their angiostatic and antipermeable properties. The rationale for the use of corticosteroids for these conditions is their ability to inhibit growth factors like vascular endothelial growth factor (VEGF). Drug delivery to the posterior segment of the eye is very challenging. One of the major concerns with intravitreal delivery is that repeated injections are disagreeable and lead to further complications. Sustained release systems including microspheres, liposomes and other implant devices offer an excellent alternative to multiple intravitreous injections.
520 $a The development of drug delivery systems is becoming important in the treatment of vitreoretinal diseases not only to facilitate drug efficacy but also to attenuate the side effects. These systems can enhance the permeation of the drug, help in controlled release of the drug. Biodegradable poly(lactide-co-glycolide) corticosteroid nanoparticles were prepared and characterized for size, drug encapsulation and in vitro drug release. In order to obtain nanoparticles of desired size and drug loading, it is important to understand the effect of various formulation variables on particle characterization. Here we studied the effect of polymer, drug and surfactant concentration. Increasing the polymer concentration increased the size of the particles. While increase in surfactant concentration decreased the size of the particles and also drug loading.
520 $a Cell culture studies were conducted to understand the effect of the corticosteroid nanoparticles on cell toxicity, cell uptake and VEGF secretion. Decrease in toxicity was seen with nanoparticles and use of soft steroid. The uptake of the particles was time and concentration dependent.
520 $a Finally, we investigated the efficacy of intravitreal corticosteroid loaded nanoparticles on experimental choroidal neovascularization in a laser-induced mice model. The corticosteroid nanoparticles showed a significant decrease in neovascularization area compared to the control indicating that corticosteroid-loaded polymer nanoparticles can inhibit the development of experimental choroidal neovascularization.
590 $a School code: 0070.
650 4 $a Health Sciences, Ophthalmology. $3 1019445
650 4 $a Health Sciences, Pharmacy. $3 1017737
690 $a 0381
690 $a 0572
710 2 $a University of Florida. $3 718949
773 0 $t Dissertation Abstracts International $g 70-02B.
790 $a 0070
790 1 0 $a Hochhaus, Guenther, $e advisor
791 $a Ph.D.
792 $a 2008
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3347160